The U.S. FDA has issued a draft guidance for devices intended to address opioid use disorder (OUD), a problem with a massive public health footprint that has defied the efforts of public health programs. The draft guidance highlights some of the difficulties in executing pivotal studies for these devices, but the FDA’s July 27 press omits any mention of a 2018 innovation challenge for this category of devices, a programmatic effort that seems to have yielded little in the way of tangible results.

State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism.